Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations.
Dumbrava EI, Brusco L, Daniels M, Wathoo C, Shaw K, Lu K, Zheng X, Strong L, Litton J, Arun B, Eterovic AK, Routbort M, Patel K, Qi Y, Piha-Paul S, Subbiah V, Hong D, Rodon J, Kopetz S, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F.
Dumbrava EI, et al. Among authors: daniels m.
JCO Precis Oncol. 2019;3:PO.18.00143. doi: 10.1200/PO.18.00143. Epub 2019 Apr 11.
JCO Precis Oncol. 2019.
PMID: 31517177
Free PMC article.